Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorEmory University

About this trial

This clinical trial develops and studies how well mobile health (m-Health) patient navigation (PN) strategies work to improve screening and the early detection of breast cancer in women accessing primary care clinics in Kenya. Although highly curable, breast cancer kills thousands of women in developing countries yearly. Mammography (MMG) is used for the early detection of breast cancer by creating a picture of the breast using film or a computer. Despite the availability of MMG in all 47 counties in Kenya, screening remains low in eligible women. Early detection of breast cancer may also be improved through access to high quality clinical breast exams (CBE). However, primary care providers in Kenya face barriers to incorporating CBE into practice, including limited patient awareness of breast cancer screening. m-Health uses applications on mobile phones to deliver PN directly to the patients. The PN strategies in this study include digital platforms and tools to help with education, reminders, navigation, and motivation around breast cancer screening. This may improve screening and the early detection of breast cancer in women accessing primary care clinics in Kenya.

Eligibility criteria

Qualifiers

AIM 1: All members of BREAKTHROUGH's Stakeholder Advisory Board (SAB) breast cancer working group

AIM 1: Participants (patients and health providers) from primary health care clinics in Nairobi County

AIM 1: Will include women (patients) aged over 35 years and speak either Kiswahili or English

Have never undergone MMG screening

Disqualifiers

AIM 1: Those who will be unwilling to consent and those who are unable to consent will be excluded from the study

AIM 2: Those who will be unwilling to consent and those who are unable to consent will be excluded from the study

AIM 3: Women undergoing breast cancer treatment and women aged 70 years and above will be excluded

AIM 4: Members of SAB breast cancer group, and health facilities leadership who will be unwilling and unable to consent will be excluded

Trial design

Treatments tested in this trial

  • Best Practice
  • Discussion
  • Interview - Stakeholder
  • Interview - Key Informant
  • Interview - Ancillary studies
  • Patient Navigation - C Components
  • Patient Navigation - B components
  • Patient Navigation - A components
  • Survey Administration
  • Survey Administration - Ancillary studies

Treatment groups

800 Participants
are divided into 11 treatment groups

11

Treatment groups

See each treatment group below.

Sponsors and collaborators

Emory University

Lead sponsor

National Cancer Institute (NCI)

Collaborator